ストックスクリーナーアプリを入手
0.5455
5.10%
-0.0293
アフターアワーズ：
.56
0.0145
+2.66%
前日終値:
$0.5748
開ける：
$0.5651
24時間の取引高:
885.68K
Relative Volume:
0.18
時価総額：
$16.52M
収益：
-
当期純損益:
$-29.77M
株価収益率:
-0.0357
EPS:
-15.2954
ネットキャッシュフロー:
$-24.23M
1週間 パフォーマンス:
-8.49%
1か月 パフォーマンス:
-3.79%
6か月 パフォーマンス:
-56.71%
1年 パフォーマンス:
-78.61%
1日の値動き範囲:
$0.5446
$0.5819
1週間の範囲:
$0.54
$0.6085
52週間の値動き範囲:
$0.25
$3.6499
Moleculin Biotech Inc Stock (MBRX) Company Profile
MBRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
0.5455 | 18.34M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.18 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.65 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.20 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
708.09 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
308.91 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-09 | 再開されました | H.C. Wainwright | Buy |
| 2025-02-12 | ダウングレード | Maxim Group | Buy → Hold |
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
Moleculin Biotech Inc (MBRX) 最新ニュース
Moleculin Biotech Releases New Corporate Presentation - TipRanks
Statistical indicators supporting Moleculin Biotech Inc.’s strengthJuly 2025 Trends & Growth Oriented Trade Recommendations - Newser
Using Bollinger Bands to evaluate Moleculin Biotech Inc.Earnings Overview Summary & Community Consensus Picks - Newser
Will Moleculin Biotech Inc. stock recover after recent drop2025 Market Overview & Smart Allocation Stock Reports - Newser
Custom watchlist performance reports with Moleculin Biotech Inc.July 2025 Snapshot & Capital Efficient Trading Techniques - Newser
Using RSI to spot recovery in Moleculin Biotech Inc.July 2025 Earnings & Trade Opportunity Analysis Reports - Newser
What’s the recovery path for long term holders of Moleculin Biotech Inc.Recession Risk & Safe Entry Point Identification - Newser
Has Moleculin Biotech Inc. Stock Ever Crashed Historical Volatility ReviewShare Buyback & Consistent Income Trade Recommendations - Newser
Is Moleculin Biotech Inc. forming a breakout patternJuly 2025 Drop Watch & Real-Time Market Trend Scan - thegnnews.com
HC Wainwright Has Positive Estimate for MBRX Q3 Earnings - Defense World
How to use Fibonacci retracement on Moleculin Biotech Inc.Market Risk Summary & Safe Entry Trade Signal Reports - Newser
Using AI based signals to follow Moleculin Biotech Inc.2025 Top Decliners & Long-Term Safe Investment Plans - Newser
What’s the outlook for Moleculin Biotech Inc.’s sectorJuly 2025 Opening Moves & Risk Controlled Stock Pick Alerts - thegnnews.com
Applying Elliott Wave Theory to Moleculin Biotech Inc.2025 Institutional Moves & Weekly Breakout Opportunity Watchlist - Newser
Combining price and volume data for Moleculin Biotech Inc.Market Weekly Review & Target Return Focused Picks - Newser
Is Moleculin Biotech Inc. stock bottoming outJuly 2025 WrapUp & Expert Curated Trade Setup Alerts - Newser
Does Moleculin Biotech Inc. fit your quant trading modelJuly 2025 Closing Moves & Free Community Supported Trade Ideas - Newser
Is Moleculin Biotech Inc. stock a buy or sellJuly 2025 Selloffs & Short-Term Trading Opportunity Alerts - thegnnews.com
Webull Corporation shares rise 1.49% premarket after AIM ImmunoTech and Moleculin Biotech to present at Webull Financial Corporate Connect Webinar Series. - AInvest
Moleculin Biotech reports Q2 EPS (49c) vs. ($1.70) last year - MSN
Moleculin receives notice of intent to grant new European patent for Annamycin - MSN
Moleculin Biotech Misses Fiscal Q2 EPS - AOL.com
Moleculin Biotech to present at Webull Financial Corporate Connect webinar series - AInvest
Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - GlobeNewswire
Late-Stage Cancer Drug Developer Moleculin Showcases Pipeline at Webull Healthcare Event - Stock Titan
Moleculin Biotech Reports Q2 2025 Financial Results - MSN
Moleculin Reports Second Quarter 2025 Financial Results and Highlights - GlobeNewswire
Moleculin Biotech Inc's Q2 2025 EPS Falls Short of Analyst Estimates, Annamycin Program Advances Amid Financial Challenges - AInvest
Moleculin Biotech: A High-Risk, High-Reward Play in Oncology Innovation Amid Capital Constraints - AInvest
Moleculin's Cancer Drug Trial Grows Globally as Critical Data Readout Approaches in 2025 - Stock Titan
Promising Developments in Annamycin Drive Buy Rating for Moleculin Biotech - TipRanks
How liquid is Moleculin Biotech Inc. stockJuly 2025 Final Week & Verified Chart Pattern Signals - newsyoung.net
Moleculin Biotech (MBRX) Projected to Post Quarterly Earnings on Tuesday - Defense World
Moleculin Biotech MBRX 2025Q2 Earnings Preview Upside Potential Driven by Strategic Developments - AInvest
Short Interest in Moleculin Biotech, Inc. (NASDAQ:MBRX) Grows By 52.0% - Defense World
Heatmap analysis for Moleculin Biotech Inc. and competitorsMomentum Trend Signal Weekly Recap Summary - Newser
Moleculin Biotech shares rise 3.66% premarket after unveiling promising preclinical data for Annamycin. - AInvest
Moleculin Biotech shares fall 5.11% intraday despite promising preclinical data for Annamycin. - AInvest
Moleculin Biotech announces preclinical data of annamycin in liver cancer - TipRanks
Moleculin Biotech Reveals Promising Preclinical Data for Annamycin - TipRanks
Moleculin Biotech Highlights Annamycin's Potential Against Liver Cancers with Promising Preclinical Data - Quiver Quantitative
Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment - GlobeNewswire
Revolutionary Cancer Treatment: Moleculin's Annamycin Targets 3 Types of Liver Cancer Without Heart Risks - Stock Titan
Moleculin Biotech shares rise 5.55% intraday after unveiling promising preclinical data for Annamycin. - AInvest
What is Moleculin Biotech Inc. company’s growth strategyMaximize returns with expert trading insights - Jammu Links News
Is Moleculin Biotech Inc. a good long term investmentAchieve unparalleled market performance - Jammu Links News
How does Moleculin Biotech Inc. compare to its industry peersInvest smarter with high-probability setups - Jammu Links News
Is it the right time to buy Moleculin Biotech Inc. stockUnlock real-time trading signals for gains - Jammu Links News
What makes Moleculin Biotech Inc. stock price move sharplyBuild a diversified portfolio for steady profits - Jammu Links News
Moleculin Biotech Releases Corporate Presentation Update - AInvest
What are the latest earnings results for Moleculin Biotech Inc.Capitalize on emerging trends for profits - Jammu Links News
Moleculin Biotech Inc (MBRX) 財務データ
収益
当期純利益
現金流量
EPS
Moleculin Biotech Inc (MBRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| KLEMP WALTER V | CEO and President |
Jun 23 '25 |
Buy |
0.37 |
675,675 |
250,000 |
743,607 |
0.95%
0.90%
大文字化:
|
ボリューム (24 時間):